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ABSTRACT 
Total of 8 formulations of in situ gels of Levofloxacin hydrochloride were prepared by pH triggered in situ gelling system using 
different polymers like sodium alginate as gelling agent, Noveon AA-1 polycarbophil and HPMC E50LV as viscosity enhancing 
agent and benzalkonium chloride as preservative. All the prepared formulations were clear and the visual appearance was found to 
be transparent. The pH of the prepared formulations was ranged between 6.50and 7.00. The drug content varied between 96.84 ± 
0.396 and 99.65±0.489 % which indicated that the uniform distribution of drug was found in all the prepared formulations. Among 
all the formulations, the formulations A4 and A8 showed better gelling capacity. The shear rate on the preparation was large during 
the blinking stage. From the in vitro drug release profile the formulations A4 and A8 was selected as the best formulations and these 
formulations were used for further studies such as mechanism of drug release, sterility, antimicrobial efficacy, ocular irritation and 
accelerated stability. Both formulations provided good fit to the Higuchi model. According to this model, the drug release from these 
gels may be controlled by diffusion through the micro-pores. The selected formulations showed good anti-microbial action against 
the organisms and ocular irritation studies revealed that the selected formulations were good with non-irritation and there were no 
ocular damage or abnormal clinical signs. During and at the end of the accelerated stability study, the selected formulations did not 
undergo any chemical changes/interaction and remained stable during the study period and showed almost similar physical stability 
and drug content.  
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INTRODUCTION 
Conventional liquid ophthalmic preparations reveal low 
bioavailability because of a steady lacrimal drainage in 
the eye. The average drainage of an instilled drug 
quantity commences instantly upon instillation and is 
basically accomplished within 5 min. Typical 
ophthalmic bioavailability (1–10%) are achieved owing 
to the short pre-corneal residence time of ophthalmic 
solutions. As a result there is a need for recurrent 
instillation of concentrated solutions to attain the 
preferred curative effect
1
. 
Ocular drug delivery is one of the major challenging and 
motivating activities which the pharmaceutical scientists 
are facing now a day, the main difficulty encountered to 
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the pharmaceutical scientists is fast pre-corneal removal 
of the drug, ensuing in deprived bioavailability and 
healing response because of high lacrimal fluid yield. In 
situ formed gels are liquid which upon insertion, 
experience phase conversion in the cul de sac of eye to 
form a visco-elastic gel and these formed gels tender a 
reaction to environmental changes. In the last few years, 
a notable number of pH, novel temperature, and ion 
induced in situ gel forming systems have been reported 
for constant ocular delivery of drugs
2
. The reduced 
bioavailability and curative response showed by 
conventional ocular solutions due to quick pre-corneal 
drug elimination may be sweeped over by the use of a 
gel system which are instilled into the cul de sac as a 
drop and which undergoes a sol-gel conversion in eye
3
. 
LEV, Biopharmaceutical Classification System I, is a 
broad spectrum anti-infective agent, under the third 
generation fluoroquinolone derivative mainly used in the 
infection of the eye such as acute conjunctivitis. The 
recommended dosage of LEV for the treatment of 
bacterial conjunctivitis is 1 or 2 drops of 0.5% solution 
in the affected eyes for every 2 hours upto 8 times for 2 
days, then 1 or 2 drops every 4 hours up to 4 times for 
next 5 days
4
. LEV is quickly and fully absorbed 
subsequent to oral administration. Peak plasma 
concentrations are typically attained one to two hours 
subsequent to oral dose. The normal terminative plasma 
elimination half-life of levofloxacin is ranging from 
around 6 to 8 hours consequent to single or multiple 
doses of levofloxacin administered either intravenously 
or orally
5
. 
In the present study an endeavor was prepared to 
develop an in situ ocular gel of LEV to increase ocular 
contact time, enhance the corneal permeability and site 
specificity for the better treatment of conjunctivitis and 
corneal ulceration with reduced adverse effects and 
better patient compliance. 
MATERIALS AND METHODS 
Materials 
Levofloxacin (LEV) was obtained as a gift sample from 
Caplin Point Laboratories Ltd, Chennai, India. 
Hydroxypropyl methylcellulose (HPMC E50LV), 
Noveon AA-1polycarbophil, Sodium alginate, 
Benzalkonium chloride, Sodium chloride and Sodium 
hydroxide were purchased from SD Fine Chemicals, 
Bangalore, India. All the chemicals and reagents used 
were of analytical grade. 
Methods 
Formulation of in situ gels of LEV  
The composition of different formulations of LEV in 
situ ocular gels is shown in Table 1. The sodium 
chloride (0.9% w/v) was dissolved in 50 mL of distilled 
water and viscosity enhancifier was added to the above 
solution and stirred slowly with a magnetic stirrer. Care 
was taken that no lumps were formed during stirring. 
The polymers were sprinkled over this solution and 
allowed to hydrate overnight and stirred using a 
magnetic stirrer. LEV was dissolved in phosphate buffer 
(pH 7.4) and benzalkonium chloride was added and the 
solution was filtered through 0.2 μm cellulose acetate 
membrane filter. The drug solution was added to the 
polymeric solution under constant stirring until a 
uniform solution was obtained. The pH of the 
formulation was then adjusted to 6.50 using 0.1 N 
NaOH. The developed formulations were filled in glass 
vials, closed with gray butyl rubber closures and sealed 
with aluminium caps. The formulations in their final 
pack were subjected to terminal sterilization by 
autoclaving at 121
° 
C at 15 psi for 20 min
6
. 
 
Table 1: Formulation of in situ ocular gel of LEV 
Compositions Concentration  (% w/v) 
A1 A2 A3 A4 A5 A6 A7 A8 
Levofloxacin  0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
HPMC E50LV 0.2 0.3 0.4 0.5 0.2 0.3 0.4 0.5 
Noveon AA-1 polycarbophil 0.5 0.5 0.5 0.5 - - - - 
Sodium alginate - - - - 0.5 0.5 0.5 0.5 
Benzalkonium chloride 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 
Sodium chloride 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 
Sodium hydroxide q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Phosphate buffer     pH 7.4 (mL) 100 100 100 100 100 100 100 100 
 
Evaluations  
Clarity, visual appearance, pH and Drug content 
The prepared formulations were observed for 
appearance and clarity by visually adjacent to black and 
white surroundings. The surface pH of the in situ ocular 
gels were determined by keeping the digisun digital pH 
meter on the formulations and allowed equilibrates for 
one minutes
7
. For drug content, sample (1 mL) was 
allowed to dissolve in 10 mLof STF solution. Aliquot of 
1 mL was withdrawn and further diluted to 10 mL with 
STF. The resultant solution was filtered through filter 
paper and the amounts of LEV present in the in situ 
ocular gels are determined using UV Spectrophotometer 
at 287nm (Shimadzu 1800, Japan). 
In vitro gelation studies 
The gelling capability of the prepared formulation was 
determined by introducing a drop of the formulation in a 
vial containing 2 mL of freshly prepared STF and 
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visually observed. The time taken for its gelling was 
noted
8,9
.  
Rheological studies 
The Brookfield viscometer LVDV-E was used to 
measure the viscosity of the LEV in situ ocular gels. The 
in situ gel formulations were placed in the sampler tube. 
The samples were analyzed by a circulating shower at 37 
°C ± 0.5 °C linked to the viscometer adaptor prior to 
every determinations. The angular velocity of the 
spindle was increased from 1 to 4 rpm and the viscosity 
of the formulation was measured 
10, 11
. 
In vitro drug release studies 
Modified diffusion apparatus was used to carry out the 
in vitro release of LEV from developed in situ ocular 
gels and STF (pH7.4) was used as a diffusion medium
12
. 
The soaked cellophane membrane in the diffusion 
medium for the night, was fixed to one end of a specially 
designed glass cylinder which was opened at both ends. 
The LEV ocular gel was accurately placed into the glass 
cylinder (donor compartment) and this cylinder was 
immersed in a beaker (receptor compartment) containing 
50 mL of diffusion medium at a 37 ± 2 °C with 50 rpm, 
so that the membrane touches the surface of the medium. 
Sample (1 mL) was withdrawn at a predetermined time 
intervals (1, 2, 3, 4, 5, 6, 7 and 8 hours) and replaced 
with an equal volume of fresh diffusion medium. The 
aliquots were diluted with the diffusion medium and 
assayed at 287 nm using UV Spectrophotometer 
(Shimadzu 1800, Japan). Parallel 2 mL of marketed 
formulation of Levofloxacin 0.5 % (5mg/ml) - Quixin 
were studied in the similar manner. The mechanism of 
drug release from the ocular gel was determined by 
finding the best fit of the release data to Higuchi and 
Korsmeyer-Peppas plots. The release rate constants ‘k’ 
and ‘n’ of each model were calculated by linear 
regression analysis using Microsoft Excel 2010 
software. Coefficients of determination (r
2
) were used to 
evaluate the accuracy of the fit
13, 14
. 
Sterility
 
Direct inoculation method was used to perform the 
sterility of the prepared formulations. From the test 
solution (2 mL) was withdrawn using a sterile pipette 
and aseptically transferred to fluid thioglycolate medium 
(20 mL) and soyabean-casein digest medium (20 mL) 
separately. After inoculation the media was incubated 
for not less than 14 days at 30-35 °C in the case of fluid 
thioglycolate medium and 20-25 °C in the case of 
soyabean-casein digest medium
15
. 
Antimicrobial efficacy studies 
The drug was allowed to diffuse through a solid agar 
medium. The standard minimum inhibitory 
concentration (MIC 2 μg/mL) of LEV and developed 
formulations containing LEV were prepared. 
Antimicrobial activity was determined by agar diffusion 
test employing cup plate technique. Staphylococcus 
aureus, Pseudomonas aeruginosa were used as the test 
organisms to study the antimicrobial efficacy (biological 
activity). The standard minimum inhibitory 
concentration (MIC 2 μg/mL) of control and developed 
formulations (10 μg/mL) containing LEV were prepared. 
The solutions were poured in to cups bored into sterile 
nutrient agar previously seeded with test organisms 
(Pseudomonas aeruginosa, and Staphylococcus aureus). 
The drug was allowed to diffuse through a solid agar 
medium. After the diffusion of the solutions for 2 hours, 
the agar plates were incubated at 37 ºC for 24 hours. The 
Zone of inhibition (ZOI) was measured around each cup 
and compared with that of control. The entire operation 
except the incubation was carried out in a laminar 
airflow unit. Both positive and negative controls were 
maintained during the study
15
. 
Ocular irritation studies 
Ocular irritation study was performed for selected 
formulations using male albino rabbits (four), each 
weighing about 2 to 3 kg. 0.1 mL of the selected sterile 
LEV formulation was instilled in to cul-de-sac twice a 
day for a period of 14 days. The rabbits were monitored 
periodically for redness, swelling, watering of the eye
16
. 
Accelerated stability studies 
Selected sterile LEV formulations were filled in glass 
vials, closed with gray butyl rubber closures and sealed 
with an aluminium caps. The vials contain optimized 
formulation were kept in stability chamber, maintained 
at 40 ± 2°C and 75 ± 5 % RH for one month. Samples 
were withdrawn weekly and estimated for drug content, 
pH, visual appearance, gelling capacity and in vitro drug 
release
17
.  
RESULTS AND DISCUSSION 
Evaluation of in situ gels of LEV Hydrochloride  
Total of 8 formulations of in situ gels of Levofloxacin 
hydrochloride were prepared by pH triggered in situ 
gelling system using different polymers like sodium 
alginate as gelling agent, Noveon AA-1 polycarbophil 
and HPMC E50LV as viscosity enhancing agent and 
benzalkonium chloride as preservative.  
Appearance, Clarity, Determination of pH and Drug 
content 
The visual appearance, clarity and the pH of the 
prepared formulations are shown in Table 2. All the 
prepared formulations were clear and the visual 
appearance was found to be transparent. Terminal 
sterilization by autoclaving had no effect on 
physicochemical properties and the clarity of the 
formulations. The pH, solubility and stability is one of 
the most significant factor concerned in the ophthalmic 
preparation. The two areas of considerable significance 
are the effect of pH and stability of the prepared 
formulation. During the formulation of in situ gels, care 
has been taken that there should not be any irritation 
while administration. The pHof the prepared 
formulations was ranged between 6.50 and 7.00. The 
drug content varied between 96.84 ± 0.396 % and 
99.65±0.489 % which indicated that the uniform 
distribution of drug was found in all the prepared 
formulations. Among all the formulations, formulation 
code A4 showed maximum drug content.  
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Table 2: Appearance, Clarity, pH and Drug content of in situ ocular gels of LEV 
Formulation Code Appearance Clarity pH
*
 Drug content (%)
*
 
A1 Transparent Clear 6.70 97.57±0.561 
A2 Transparent Clear 6.62 97.96±0.624 
A3 Transparent Clear 6.93 98.64±0.341 
A4 Transparent Clear 6.98 99.65±0.489 
A5 Transparent Clear 6.50 96.84±0.396 
A6 Transparent Clear 6.82 98.12±0.474 
A7 Transparent Clear 6.78 98.61±0.547 
A8 Transparent Clear 7.00 99.09±0.647 
                         *Mean ± S.D, n=3 
 
In vitro gelation studies 
Among all the formulations, the formulations A4 and A8 
showed better gelling capacity Table 3. This may be due 
to the higher uptake capacity of the polymers. 
Rheological studies 
The rheological properties (pre gelation and post 
gelation viscosity studies) of the prepared in situ ocular 
gels of LEVare shown in Figure 1- 2. The results 
showed that the viscosity of all the prepared 
formulations reduced as the shear rate increased, which 
indicated the character of pseudo plastic fluid. The shear 
rate on the preparation was large during the blinking 
stage. If the viscosity is too high, this will result in 
irritation in the eye and it is too low, it may produce 
increased drainage. Therefore, the formulation should 
have optimum viscosity for easy instillation into the eye 
as liquid, which will go through a rapid sol-to-gel 
transition, hence the good gelling capacity.  
Table 3: Gelling capacity of in situ ocular gels of LEV 
Formulation code Gelling Capacity 
A1 + 
A2 + 
A3 ++ 
A4 +++ 
A5 + 
A6 + 
A7 ++ 
A8 +++ 
+Gels after few minutes and dissolves rapidly 
++ Gels immediately and remains for few hours 
+++ Gels immediately and remains for extended period of time
 
 
Figure 1: Pre-gelation viscosity studies of in situ ocular gels of LEV 
 
 Figure 2: Post-gelation viscosity studies of in situ ocular gels of LEV 
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In vitro drug release studies 
The in vitro release of LEV from the in situ ocular gelsis 
shown in Figure 3. The prolonged drug release was 
showed by the formulation A8 98.72% at a period of 8 h 
and followed by the formulation A4 96.19%. The 
formulations A3 showed 95.1% and A7 showed 97.7% 
maximum drug release for a period of 7 hours. The 
formulations A1 showed the maximum drug of release 
97.95%, A2 showed 96.34%, A5 showed 97.13% and 
A6 showed 96.54% after 6 hours. The extended period 
of drug release may be due to relaxed diffusion of drug 
from the formulations. The combinations of polymers 
might have played an important role in diffusion and 
thereby exhibit controlled drug delivery. Moreover 
formation of gel matrix between drug and polymers 
might have helped to attain the rate controlled release. 
From the in vitro drug release profile the formulations 
A4 and A8 was selected as the best formulations and 
these formulations were used for further studies such as 
mechanism of drug release, sterility, antimicrobial 
efficacy, ocular irritation and accelerated stability.
 
 
 Figure 3: In vitro drug release of the formulations A1 – A8 
Mechanism of drug release 
The mechanisms of drug release from the selected in situ ocular gels were determined by finding the best fit of release 
data to Higuchi and Korsmeyer-Peppas plots. The release rate constant ‘k’ and ‘n’ of each model were calculated by 
linear regression analysis. Co-efficient of determination (r
2
) was used to evaluate the accuracy of the fit. The r
2
, k and n 
values are shown in Table 4. 
Table 4: The r
2
, k and n values of selected formulations 
 
Both formulations provided good fit to the Higuchi 
model. According to this model, the drug release from 
these gels may be controlled by diffusion through the 
micropores. 
Sterility and Antimicrobial efficacy and Ocular 
irritation studies 
The sterility studies indicated that the selected 
formulations were sterile when incubated for a 
minimum of 14 days at 30-35 ºC in case of fluid 
thioglycolate medium and at 20-25 ºC in the case of 
soya bean-casein digest medium. The antimicrobial 
efficiency of the selected formulation is shown in Table 
5. After incubation, the result indicated that the selected 
formulations showed good anti-microbial action against 
the organisms. The ocular irritation studies revealed that 
the selected formulations were good with non-irritation 
and there were no ocular damage or abnormal clinical 
signs. 
 
Table 5: Antimicrobial studies of the selected formulations 
 
Test micro organisms 
Diameter of the zone of inhibition produced by in situ gels (mm) 
LEV A4 A8 
Staphylococcus Aureus 26 26 25 
Pseudomonas Aeruginosa 33 33 33 
 
 
Formulations  
Higuchi Korsmeyer–Peppas 
Mechanism of drug release 
r
2
 k (h
-1
) r
2
 n 
A4 0.9984 0.2552 0.9976 0.4788 Diffusion 
A8 0.9982 0.2883 0.9971 0.4979 Diffusion 
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Accelerated stability studies 
During and at the end of the accelerated stability study, 
the selected formulations did not undergo any chemical 
changes/interaction and remained stable during the study 
period and showed almost similar physical stability and 
drug content.  
CONCLUSION 
LEV is a broad spectrum anti bacterial agent used in the 
treatment of various ocular infections. In situ ocular gels 
of LEV were prepared and in vitro drug release indicated 
that it is potential drug delivery of LEV. The optimized 
formulations (A4 and A8) showed good antibacterial 
efficacy with non irritant character. In vivo studies are 
warranted to confirm these results in future. 
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